Angiostatic treatment of neuroblastoma

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2020-2023

  Wassberg, E ^a   Christofferson, R ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiostatic treatment; Anti angiogenic therapy; Neuroblastoma; TNP 470 (AGM 1470); Tumour angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE;

APOPTOSIS; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; GROWTH DISORDER; GROWTH INHIBITION; HUMAN; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SECOND CANCER; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; CYCLOHEXANES; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROGNOSIS; RATS; SESQUITERPENES;

EID: 0031408770     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00337-7     Document Type: Conference Paper

References (40)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1971;1182-1186.
2. Folkman J. Tumor angiogenesis. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, WB Saunders Co, 1995, 206-232.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
4. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
5. Gasparini G., Harris A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 13:1995;765-782.
6. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med. 73:1995;497-508.
7. Teicher B. A., Emi Y., Kakeji Y., Northey D. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer. 32A:1996;2461-2466.
8. Fox S. B., Gatter K. C., Harris A. L. Tumour angiogenesis. J Pathol. 179:1996;232-237.
9. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 32A:1996;2534-2539.
10. Nguyen M., Watanabe H., Budson A. E., et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 86:1994;356-361.
11. Perez-Atayde A. R., Sallan S. E., Tedrow U., et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 150:1997;815-821.
12. Lin R. Y., Argenta P. A., Sullivan K. M., Adzick N. S. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res. 1:1995;327-331.
13. Meitar D., Crawford S. E., Rademaker A. W., Cohn S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 14:1996;405-414.
14. Chen C., Parengi S., Tolentino M. J., Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res. 55:1995;4230-4233.
15. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, JB Lippincott Company, 1993, 739-767.
16. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
17. Wassberg E., Påhlman S., Westlin J.-E., Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res. 41:1997;327-333.
18. Biedler J. L., Roffler-Tarlov S., Schaschner M., Freedman L. S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38:1978;3751-3757.
19. Nagabuchi E., VanderKolk W. E., Une Y., Ziegler M. M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg. 32:1997;287-293.
20. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
21. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
22. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disaease. Nature Med. 1:1995;27-31.
23. Huang X., Molema G., King S., et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
24. Pasqualini R., Koivunen E., Rouslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nature Biotech. 15:1997;542-546.
25. Gasparini G., Presta M. Clinical studies with angiogenesis inhibitors. Biological rationale and challenges for their evaluation. Ann Oncol. 7:1996;441-444.
26. Holmgren L., O'Reilly M. S., Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1:1995;149-153.
27. Klauber N., Rohan R. M., Flynn E., D'Amato R. J. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med. 3:1997;443-446.
28. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9:1990;267-282.
29. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87, 1161-1169.
30. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest New Drugs. 15:1997;61-75.
31. Berlin J, Tutsch KD, Hutson P, et al. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 1997, 15, 781-789.
32. DeVore RF, Hellerqvist CG, Wakefield GB, et al. A phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997, 3, 365-372.
33. Chang E., Boyd A., Nelson C. C., et al. Successful treatment of infantile hemangiomas with interferon-α-2b. J Pediatr Hematol Oncol. 19:1997;237-244.
34. Voest E. E., Kenyon B., O'Reilly M. S., Truitt G., D'Amato R. J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 87:1995;581-586.
35. Vukanovic J., Passaniti A., Hirata T., Traystmann R. J., Hartley-Asp B., Isaacs J. T. Antiangiogenic effect of the quinoline-3-carboxamide linomide. Cancer Res. 53:1993;1833-1837.
36. Kahn J, Ruiz R, Kershmann R, et al. A phase I/II study of recombinant platelet factor 4 (rPF4) in patients with AIDS related Kaposis's sarcoma (KS). Proc Am Soc Clin Oncol 1993, 12, 50.
37. Mirza M. R., Jakobsen E., Pfeiffer P., et al. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol. 36:1997;171-174.
38. Eckhardt SG, Burris HA, Eckardt JR, et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996, 7, 491-496.
39. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:1994;4082-4085.
40. Figg WD, Pluda JM, Lush RM, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997, 17, 91-97.